🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Kopran Limited KOPRAN NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.kopran.com
Company Profile ↓
₹232.54
+51.31% 1Y
Mkt Cap₹1,122.83 Cr
P/E29.10
P/B1.65
Div. Yield1.57%
52W High₹232.54
52W Low₹106.22
Book Value₹109.82
EPS (TTM)₹7.99

Company Overview

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 29.1, below the sector median of 41.6.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.29.

Recent Developments

  • Mar 2026 Revenue of ₹675.69 Cr (+8.3% YoY); net profit ₹25.73 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +8.3%, earnings -33.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR -1.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.22%
1 Year:8.28%

Compounded Profit Growth

5 Years:-1.87%
1 Year:-33.26%

Stock Price Performance

1 Year:+51.31%
6 Months:+92.59%
3 Months:+28.80%
1 Month:+24.06%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹106.22 ₹232.54
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)74.21 · Overbought
Price Performance
1M+24.06%
3M+28.80%
6M+92.59%
1Y+51.31%
Valuation vs Sector

P/E of 29.10 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -1.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
29.10
Industry PE
41.64
Forward P/E
41.01
PEG Ratio
-
Book Value
₹109.82
Price to Book
1.65
P/S
1.28
EV/EBITDA
13.43
Dividend Yield
1.57%

Growth (CAGR)

Revenue 5Y
7.22%
Profit 5Y
-1.87%
Revenue (YoY)
8.28%
Earnings (YoY)
-33.26%

Profitability & Returns

ROCE
7.69%
ROE
4.85%
ROA
2.83%
Profit Margin
3.81%
Op Margin
9.04%
Gross Margin
32.67%
EPS (Latest Qtr)
₹3.91
EPS (TTM)
₹7.99

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
1.04
Current Ratio
1.51
Debt
₹152.69 Cr
Total Assets
₹908.36 Cr
Current Assets
₹523.18 Cr
Working Capital
₹177.00 Cr

Ownership

Promoter Holding
50.21%
Chg in Prom Hold
1.34%
FII / Inst Holding
0.19%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹1,122.83 Cr
Total Revenue (TTM)
₹675.69 Cr
EBITDA
₹60.68 Cr
Free Cash Flow
₹-37.44 L
Operating Cash Flow
₹66.75 Cr
Shares Outstanding
₹4.83 Cr
Gross Margin
32.67%
Payout Ratio
56.29%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KOPRAN Kopran Limited NSEPHARMA 232.54 29.10 ₹1,122.83 Cr 1.57% 7.69% 4.85% 7.22% -1.87%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 149.00 Cr117.00 Cr153.00 Cr159.00 Cr186.00 Cr139.00 Cr152.00 Cr166.00 Cr172.36 Cr135.22 Cr117.91 Cr194.28 Cr234.02 Cr
Cost of Revenue --------115.36 Cr85.40 Cr76.01 Cr131.06 Cr146.54 Cr
Gross Profit --------57.00 Cr49.81 Cr41.90 Cr63.22 Cr87.47 Cr
Operating Expenses 137.00 Cr111.00 Cr130.00 Cr135.00 Cr164.00 Cr121.00 Cr137.00 Cr146.00 Cr43.78 Cr39.94 Cr43.22 Cr47.41 Cr51.42 Cr
Operating Income 9.00 Cr3.00 Cr20.00 Cr21.00 Cr18.00 Cr14.00 Cr11.00 Cr16.00 Cr13.22 Cr9.87 Cr-1.32 Cr15.82 Cr36.06 Cr
EBITDA 12.00 Cr6.00 Cr23.00 Cr24.00 Cr22.00 Cr18.00 Cr15.00 Cr20.00 Cr20.35 Cr16.69 Cr-5.25 Cr17.83 Cr33.04 Cr
Interest Expense 2.00 Cr2.00 Cr2.00 Cr2.00 Cr3.00 Cr2.00 Cr2.00 Cr2.00 Cr2.77 Cr2.54 Cr2.09 Cr2.67 Cr3.17 Cr
Pretax Income 11.00 Cr4.00 Cr18.00 Cr20.00 Cr25.00 Cr15.00 Cr10.00 Cr14.00 Cr13.71 Cr9.89 Cr-11.63 Cr10.74 Cr25.35 Cr
Tax Provision 2.86 Cr92.00 L4.50 Cr4.60 Cr6.50 Cr3.75 Cr2.30 Cr3.50 Cr4.03 Cr2.44 Cr-1.70 Cr1.40 Cr6.48 Cr
Net Income 8.00 Cr3.00 Cr14.00 Cr16.00 Cr19.00 Cr11.00 Cr7.00 Cr10.00 Cr9.68 Cr7.45 Cr-9.92 Cr9.34 Cr18.87 Cr
Diluted EPS 1.670.572.863.283.862.301.532.162.001.54-2.061.933.91

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 326.00 Cr296.00 Cr310.00 Cr313.00 Cr358.00 Cr360.00 Cr492.00 Cr-548.18 Cr614.59 Cr623.99 Cr675.69 Cr
Cost of Revenue --------374.00 Cr416.21 Cr418.79 Cr454.96 Cr
Gross Profit --------174.18 Cr212.65 Cr205.20 Cr220.73 Cr
Operating Expenses 294.00 Cr266.00 Cr274.00 Cr283.00 Cr312.00 Cr313.00 Cr410.00 Cr-128.89 Cr151.13 Cr147.89 Cr159.66 Cr
Operating Income 21.00 Cr22.00 Cr28.00 Cr22.00 Cr37.00 Cr37.00 Cr72.00 Cr-45.29 Cr61.53 Cr57.31 Cr61.06 Cr
EBITDA 31.00 Cr30.00 Cr36.00 Cr31.00 Cr46.00 Cr47.00 Cr82.00 Cr-53.28 Cr86.82 Cr75.26 Cr60.68 Cr
Interest Expense 13.00 Cr13.00 Cr14.00 Cr9.00 Cr9.00 Cr9.00 Cr6.00 Cr-4.50 Cr6.39 Cr7.72 Cr8.85 Cr
Pretax Income -39.00 Cr11.00 Cr25.00 Cr23.00 Cr32.00 Cr28.00 Cr83.00 Cr-36.07 Cr67.54 Cr51.95 Cr34.36 Cr
Tax Provision 0-05.00 Cr2.30 Cr7.68 Cr7.28 Cr21.58 Cr-8.83 Cr16.59 Cr13.40 Cr8.62 Cr
Net Income -39.00 Cr11.00 Cr20.00 Cr20.00 Cr24.00 Cr21.00 Cr62.00 Cr-27.23 Cr50.96 Cr38.55 Cr25.73 Cr
Diluted EPS -9.522.484.604.745.554.8614.2413.775.6510.557.99-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 275.00 Cr264.00 Cr298.00 Cr315.00 Cr351.00 Cr370.00 Cr439.00 Cr-649.70 Cr743.25 Cr844.01 Cr908.36 Cr
Current Assets --------399.07 Cr454.03 Cr509.75 Cr523.18 Cr
Cash & Equivalents --------7.40 Cr8.09 Cr19.47 Cr68.20 L
Inventory --------130.61 Cr138.49 Cr169.42 Cr164.21 Cr
Receivables --------162.56 Cr212.33 Cr214.93 Cr262.66 Cr
Total Liabilities --------210.45 Cr252.00 Cr325.66 Cr378.08 Cr
Current Liabilities --------176.97 Cr218.53 Cr288.97 Cr346.18 Cr
Long Term Debt --------17.89 Cr16.60 Cr16.48 Cr13.95 Cr
Total Debt 86.00 Cr80.00 Cr95.00 Cr89.00 Cr97.00 Cr88.00 Cr66.00 Cr-75.24 Cr99.23 Cr147.79 Cr152.69 Cr
Total Equity 90.00 Cr100.00 Cr124.00 Cr144.00 Cr168.00 Cr189.00 Cr245.00 Cr-439.25 Cr491.25 Cr518.35 Cr530.28 Cr
Shares Outstanding --------4.82 Cr4.82 Cr4.83 Cr4.83 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 46.00 Cr29.00 Cr16.00 Cr26.00 Cr25.00 Cr31.00 Cr60.00 Cr-34.02 Cr43.26 Cr41.94 Cr66.75 Cr
Investing Cash Flow -10.00 Cr-9.00 Cr-18.00 Cr-11.00 Cr-25.00 Cr-13.00 Cr-25.00 Cr--12.65 Cr-43.55 Cr-56.43 Cr-64.60 Cr
Financing Cash Flow -37.00 Cr-19.00 Cr2.00 Cr-15.00 Cr-1.00 Cr-18.00 Cr-35.00 Cr--19.84 Cr98.85 L25.87 Cr-20.94 Cr
Capital Expenditure -11.00 Cr-11.00 Cr-16.00 Cr-12.00 Cr-31.00 Cr-14.00 Cr-17.00 Cr--61.05 Cr-56.61 Cr-58.92 Cr-67.13 Cr
Free Cash Flow 35.00 Cr18.00 Cr-014.00 Cr-6.00 Cr17.00 Cr43.00 Cr--27.02 Cr-13.36 Cr-16.98 Cr-37.44 L
Net Change in Cash -00-0-0-000-1.53 Cr69.46 L11.38 Cr-18.79 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------31.8%34.6%32.9%32.7%
Operating Margin % 6.4%7.4%9.0%7.0%10.3%10.3%14.6%-8.3%10.0%9.2%9.0%
Net Margin % -12.0%3.7%6.5%6.4%6.7%5.8%12.6%-5.0%8.3%6.2%3.8%
ROE % -43.3%11.0%16.1%13.9%14.3%11.1%25.3%-6.2%10.4%7.4%4.9%
ROCE % --------9.6%11.7%10.3%10.9%

Shareholding Pattern

Insiders
50.21%
Institutions
0.19%
Public Float
0.38%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KOPRAN

Google News hu, 03 Sep 2026

Kopran Ltd. Share Price News With Healthcare Sector View - Univest

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE8wWmR3c3Yzc0lBeXJUbFExbERwYjhacVMydzJLb1UxN1VFSHA2NUR1Z2NVamZjVTQ2cnN3TjlNaG5uRkNPQ1NJZ1hETnVHN3JWckNjVEdUMm80RGR4eEJoeElDRzZ3R2JwTmVnSHN1WGtFYTljRUE?oc=5" target="_blank">Kopran L…

Google News Fri, 06 Feb 2026

We Think Kopran (NSE:KOPRAN) Is Taking Some Risk With Its Debt - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdUhkaEhHMHgxVTBRWHhWaFpSMjgza201eE1KS2wtZ3ZaTnhZZWU3N3Rja1ZVOHV5QnVPX2cyRm1pQUNZc1UzWEVva2JGVEFuXzU2dl9KOW5Zcmp3NWpoT0w0MUJyVDBOQkcxRi1VWFU3eldSZzlmbUtzSFhwbXk2LUh5ckYwbk1kLUhEeU…

Google News Sat, 15 Aug 2026

Kopran - Madhusudan Kela’s portfolio: 7 stocks rally up to 135% in CY26 - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNalk1TXFScVFtVXFvcU5pSVpjZjdTeFgta2Jqb3dLa2txOHl0cFFCOVpCOFhKV0h4enBvUFJWTHdZbHc5Q2gwZENyVkgxUFNMWUdrWTZHQ0p5YUFObnoyWmVsZ2JmVU5EeWc2emVrQjlGSlN6NEJ5djg0aHVjSlhWdFU1clNUTzA1UTJmRX…

Google News ue, 23 Jun 2026

Kopran Ltd Faces Selling Pressure; Stock Slides 2.84% from Resistance - GEX Level - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaV9RMGlDeFN0RUFMdXdET0VycXljb0JwQzk2X0hfUFNGV0NINlFwbnJ0MkZESjFBZThGZ0p1WUkwM0Y3SkhjNWlrYUtlVllET2xSaHBrZmcybm5qeWhSY1dqaDRRR1Z6WU9OeDBVM0RBZkMtSndoenNtQUo1UUVFNDJzZ2FWOFFuRTRsQU…

Google News ue, 18 Aug 2026

Kopran declares ₹3 per share dividend, approves board changes at AGM - scanx.trade

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPNWdBRFZOeHh0ZENUMGZnbmQzWURtOTR0YTI5SzZtaWpPVTZBMlFFbFpnU1pKaXBIc3Z1azdaN1VySjRGZ0RiYnZiMExtWFB5MFRZaWstdUJSU2dNcmc2Y3lLdE9hbUk5OUNZcnNfWmtQX0pWdVdrdjFUMWdKek85MHBOSmt0OFNOdE5pdk…

Google News Wed, 12 Aug 2026

Kopran Standalone June 2026 Net Sales at Rs 62.76 crore, up 18.9% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNWFlNaWM4TVByMWhocWJRSGg1V0tzSzJ0Zm11Wl9pUG1jbklTUzdoNG1yMUpFTWw1bW9nZmdBczJoelFIYmdHY2tMUmJZenlNRV9ka0dyMUp2QjBCUnZnMEFZczB6Q3FSek9lc0lBa3pqZEhWbGpUd2xGeUZyOXJhRTRSUVh0aXlCY2FIT1…

KOPRAN — Frequently Asked Questions

What is the current share price of Kopran Limited (KOPRAN)?

As of 2026-09-08 04:53 IST, Kopran Limited (KOPRAN) trades at ₹232.54 on NSE. Its 52-week range is ₹106.22 to ₹232.54.

What is the market capitalisation of KOPRAN?

Kopran Limited (KOPRAN) has a market capitalisation of ₹1,122.83 Cr on NSE.

What is the P/E ratio of KOPRAN?

KOPRAN trades at a trailing price-to-earnings (P/E) ratio of 29.10. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.65.

Does KOPRAN pay a dividend?

Kopran Limited (KOPRAN) currently offers a dividend yield of 1.57%.

What is the return on equity (ROE) of KOPRAN?

KOPRAN has a return on equity (ROE) of 4.85%. Its return on capital employed (ROCE) is 7.69%.

Is KOPRAN a good stock to buy?

This page provides a data-driven analysis of Kopran Limited (KOPRAN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space